Bladder Cancer Market Growth, Trend, Price, Demand and Forecast Bladder Cancer Market - Global Industry Analysis,

Bladder Cancer Market - Global Industry Analysis, Size, Share,
Growth, Trends, and Forecast 2017 – 2025
Bladder cancer is a urologic malignancy occurring in the tissues of the urinary bladder. It is
characterized by the uncontrolled, rapid growth of cells arising from the epithelial lining and can be
proliferating to the muscular wall of urinary bladder. The bladder or urinary bladder is a hollow organ
located in the pelvis (lower abdomen) which stores the urine drained from kidney. It is connected to
the kidney by ureters, a tube like structure. Bladder cancer is ranked as the ninth most frequently
diagnosed cancer. Region such as North America, Western and Southern Europe along with certain
countries in Western Asia or Northern Africa have recorded highest incidence rates in men. Bladder
cancer is more prevalent in men as compared to women; however, the sex ratio varied with different
countries.
Request for brochure of this report -
http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=22985
The exact causes for bladder cancer are not known. However, some of the risk factors such as
excessive smoking, tobacco consumption, continuous exposure to radiation, chronic bladder infection,
and previous cancer treatments are considered to cause bladder cancer. Bladder cancer can affect
any age group; however, it is more prevalent in adults aged over 50 years. Furthermore, the observed
trends and patterns worldwide reflect tobacco smoking as the prevalent cause of bladder cancer.
Infection with schistosoma haematobium along with other risk factors are also the major causes of
bladder cancer in selected population.
The global bladder cancer market is driven by increasing incidence of bladder cancer, leading to drug
innovations for treatment and technological advancements. Bladder cancer is more common in adults
aged over 50 years. Hence, increasing geriatric population also contributes to market growth.
Furthermore, government initiatives, increasing awareness about bladder cancer and the available
treatments, and progressive health care services with growing health care expenditure are expected
to propel the global market. However, cancer being an asymptomatic disease at initial stage, needs
accurate diagnosis at early stage. Inaccurate and unaffordable diagnosis could hamper the growth of
the market. Increasing use of generic drugs and growing patent expirations are factors responsible for
the sluggish growth of the market.
The global bladder cancer market can be segmented based on diagnosis, therapy, and region. Bladder
cancer can be diagnosed by urine lab tests, cystoscopy, biopsy, and imaging test. Urine lab tests can
be further divided into urinalysis, urine cytology, urine culture, and urine tumor marker test. The
imaging tests segment can be further divided into intravenous pyelogram (IVP), computed tomography
(CT) scan, magnetic resonance imaging (MRI) scan, and ultrasound. In terms of therapy, the market
can be segmented in to chemotherapy, radiation therapy, immunotherapy, and surgery.
Geographically, the bladder cancer market can be segmented into five major regions: North America,
Latin America, Europe, Asia Pacific, and Middle East & Africa. North America holds the major share
of the global bladder cancer market. Major share of the region is attributed to the rise in incidence of